Searched for
MAYNE PHARMA
Australian Stock Market rises, sees modest gains across indices, Mayne Pharma drops 30%; check ASX 200 top gainers and losersThe Australian stock market (ASX) saw a slight rise on Friday, though it is set for a weekly decline. The ASX showed modest gains across mo...- Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringementMayne Pharma sued India's Sun Pharma for allegedly infringing patents on IMVEXXY, a drug for menopause-related vaginal pain. The lawsuit wa...
- Dr Reddy’s Labs shares plunge 7%. Here’s whyDr Reddy's shares have slightly underperformed the Nifty Pharma index, giving returns of nearly 22% over the last 12 months versus 25% give...
- Dr Reddy's Labs Q2 Results: Profit rises 33% YoY to Rs 1,480 crore, revenue up 9%The company reported an EBITDA of Rs 2,181 crore in the September quarter, higher by 13% YoY. EBITDA margins in the same period came in at ...
- Dr Reddy's Q1 Results: Net profit rises 18% YoY to Rs 1403 croreIndian drug company Dr Reddy's plans to use its net cash surplus of INR 5,000 crore ($670m) to fund acquisitions and innovations aiming at ...
- Dr Reddy's Q1 Results: PAT up 18% YoY at Rs 1,405 crore, tops estimateThe EBITDA or earnings before interest, taxes, depreciation, and amortisation, for the quarter increased 20% on year to Rs 2,137 crore. How...
- Dr Reddy's to acquire Mayne Pharma US generic portfolio for $105 millionUnder the terms of the agreement, Dr. Reddy’s will acquire the portfolio for an upfront payment of $90 million in cash, contingent payments...
- Alembic Pharma gets USFDA nod for generic drugDoxycycline Hyclate delayed-release tablets are indicated to reduce the development of drug resistant bacteria.
- Pharma stocks crash after US lawsuit over price manipulationsThe other generic makers named in the suit include Apotex, Teva, Heritage Pharma and Par Pharma.
- Indian execs 'named' in US pharma caseThe Indian generic makers named in the lawsuit are Aurobindo, Dr Reddy’s, Emcure, Glenmark, and Zydus.
- Oil collapse hits Australian shares, but NZ up; Fed in focusAustralia's S&P/ASX 200 index declined 0.2 per cent or 8.9 points to close at 5,580.60.
- Australian shares end higher, healthcare stocks at record; NZ closedThe S&P/ASX 200 index rose 0.6 percent or 35.100 points to 6025.500.
- US probe against generic drugs overblown: ExpertsThe DoJ has in the past probed multinational drug companies for inappropriate marketing practices but the scale of investigations against t...
- DRL, Cipla, Aurobindo among others to buy products from TevaThe remedy requires Teva to divest the drug portfolio to 11 firms and marks the largest drug divestiture order in an FTC pharmaceutical mer...
- US-based Hospira to buy Orchid Chemicals' injectables biz for $400 mnOrchid Chemicals & Pharmaceuticals to sell its injectables business to the US-based Hospira for around $400 million.
- Sanofi to eclipse Sun’s Eloxatin planFrance’s largest pharma company, Sanofi-Aventis, is suing India’s Sun Pharmaceuticals and Hospira’s Mayne Pharma to prevent the latter from...
- Ranbaxy's Simvastatin to go Down Under by AugRanbaxy Laboratories is planning to launch cardiovascular drug Simvastatin in Australia this year.
- Windfall for cos eyeing US oncology marketWith anti-cancer blockbuster drugs set to go off-patent in the US in the next three to four years, generic players are gearing up to tap th...
- Hospira-Mayne deal likely to alter pharma equations hereOne of the biggest trans-continent deals in the generic pharma sector is likely open the floodgates of opportunities for the Indian pharma ...
- Claris enters pact with Mayne, SandozContinuing with its overseas expansion plans, Ahmedabad-based pharmaceutical firm Claris Lifesciences today said it had entered into strate...
Load More
